AlphaQuest LLC Sells 29,619 Shares of Intellia Therapeutics, Inc. $NTLA

AlphaQuest LLC reduced its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 57.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,215 shares of the company’s stock after selling 29,619 shares during the quarter. AlphaQuest LLC’s holdings in Intellia Therapeutics were worth $208,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its position in shares of Intellia Therapeutics by 23.5% in the second quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 100,000 shares of the company’s stock worth $938,000 after purchasing an additional 19,000 shares during the period. D.A. Davidson & CO. boosted its position in shares of Intellia Therapeutics by 108.0% in the second quarter. D.A. Davidson & CO. now owns 54,120 shares of the company’s stock worth $508,000 after purchasing an additional 28,100 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Intellia Therapeutics in the second quarter worth approximately $166,000. Harbour Investments Inc. boosted its position in shares of Intellia Therapeutics by 27.2% in the second quarter. Harbour Investments Inc. now owns 6,633 shares of the company’s stock worth $62,000 after purchasing an additional 1,419 shares during the period. Finally, CWM LLC grew its holdings in Intellia Therapeutics by 22.9% during the 2nd quarter. CWM LLC now owns 18,331 shares of the company’s stock valued at $172,000 after buying an additional 3,419 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Price Performance

NTLA stock opened at $12.62 on Monday. The company has a market capitalization of $1.35 billion, a PE ratio of -2.69 and a beta of 2.45. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.25. The firm’s 50-day moving average is $17.12 and its 200 day moving average is $12.38.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The firm had revenue of $14.25 million for the quarter, compared to analyst estimates of $12.26 million. During the same quarter last year, the firm posted ($1.52) earnings per share. The business’s revenue for the quarter was up 104.3% on a year-over-year basis. Sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on NTLA shares. Robert W. Baird set a $9.00 price objective on shares of Intellia Therapeutics in a report on Thursday. Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday, October 28th. William Blair lowered shares of Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 27th. Chardan Capital dropped their target price on shares of Intellia Therapeutics from $60.00 to $48.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Finally, Wedbush set a $9.00 target price on shares of Intellia Therapeutics in a research report on Thursday. Twelve research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Hold” and an average price target of $23.74.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, Director William J. Chase acquired 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was acquired at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the purchase, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. The trade was a 288.24% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Michael P. Dube sold 1,871 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the transaction, the chief accounting officer owned 55,266 shares of the company’s stock, valued at approximately $960,523.08. This represents a 3.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.10% of the stock is currently owned by insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.